Table 3.
Analysis of three-biomarker combinations for distinguishing FTC from FA.
| Biomarker | c-value | Immunostaining intensity cutoff for FTC detection | Sensitivity | Specificity | NPV | PPV |
|---|---|---|---|---|---|---|
| FTC versus FA | ||||||
| ASNS, CRYAB, and TYRP1 | 0.824 | >−0.286 | 0.72 | 0.86 | 0.92 | 0.56 |
| ASNS, CA4, and TYRP1 | 0.815 | >−0.011 | 0.72 | 0.88 | 0.93 | 0.60 |
| ASNS, TRAP22, and TYRP1 | 0.812 | >−0.414 | 0.72 | 0.78 | 0.92 | 0.45 |
| ASNS, CD44H, and TYRP1 | 0.804 | >−0.309 | 0.72 | 0.80 | 0.92 | 0.47 |
| ASNS, PPIF, and TYRP1 | 0.800 | >−0.431 | 0.72 | 0.73 | 0.91 | 0.40 |
| ASNS, GDF15, and TYRP1 | 0.794 | >−0.192 | 0.72 | 0.80 | 0.92 | 0.47 |
| ASNS, PCSK2, and TYRP1 | 0.793 | >−0.595 | 0.76 | 0.69 | 0.92 | 0.38 |
| ASNS, FGF13, and TYRP1 | 0.789 | >−0.653 | 0.80 | 0.65 | 0.93 | 0.37 |
| ASNS, CA4, and PCSK2 | 0.782 | >−0.556 | 0.72 | 0.71 | 0.91 | 0.39 |
| CA4, CRYAB, and PPIF | 0.773 | >−0.553 | 0.72 | 0.76 | 0.92 | 0.42 |
| ASNS, CA4, and CRYAB | 0.758 | >−0.844 | 0.72 | 0.63 | 0.90 | 0.33 |
| Angioinvasive FTC versus FA | ||||||
| ASNS, CRYAB, and TYRP1 | 0.941 | >−0.315 | 0.73 | 0.90 | 0.98 | 0.27 |
| ASNS, CA4, and TYRP1 | 0.921 | >−0.352 | 0.87 | 0.88 | 0.99 | 0.27 |
| ASNS, GDF15, and TYRP1 | 0.898 | >−0.391 | 0.73 | 0.86 | 0.98 | 0.21 |
| ASNS, TFF3, and TYRP1 | 0.895 | >−0.391 | 0.73 | 0.84 | 0.98 | 0.19 |
| ASNS, GAL3, and TYRP1 | 0.891 | >−0.369 | 0.73 | 0.90 | 0.98 | 0.27 |
| ASNS, PCSK2, and TYRP1 | 0.890 | >−0.601 | 0.73 | 0.86 | 0.98 | 0.21 |
| ASNS, GOT1, and TYRP1 | 0.890 | >−0.624 | 0.73 | 0.84 | 0.98 | 0.19 |
| ASNS, ECAD, and TYRP1 | 0.888 | >−0.635 | 0.71 | 0.83 | 0.98 | 0.18 |
| ASNS, TRAP22, and TYRP1 | 0.884 | >−0.712 | 0.73 | 0.82 | 0.98 | 0.17 |
| ASNS, TYRP1, and X123 | 0.877 | >−0.763 | 0.71 | 0.83 | 0.98 | 0.18 |
| ASNS, CA4, and CRYAB | 0.815 | >−1.372 | 0.73 | 0.67 | 0.98 | 0.11 |
| Widely angioinvasive FTC versus FA | ||||||
| ASNS, CA4, and TYRP1 | 0.943 | >−0.538 | 0.75 | 0.94 | 0.99 | 0.34 |
| ASNS, CRYAB, and TYRP1 | 0.926 | >−0.857 | 0.75 | 0.86 | 0.99 | 0.18 |
| ASNS, TFF3, and TYRP1 | 0.915 | >−0.878 | 0.75 | 0.86 | 0.99 | 0.18 |
| ASNS, PPIF, and TYRP1 | 0.914 | >−0.690 | 0.75 | 0.90 | 0.99 | 0.23 |
| ASNS, PCSK2, and TYRP1 | 0.908 | >−0.847 | 0.75 | 0.88 | 0.99 | 0.20 |
| ASNS, FGF13, and TYRP1 | 0.905 | >−0.675 | 0.75 | 0.90 | 0.99 | 0.23 |
| ASNS, GDF15, and TYRP1 | 0.904 | >−0.739 | 0.75 | 0.90 | 0.99 | 0.23 |
| ASNS, TRAP22, and TYRP1 | 0.902 | >−0.964 | 0.75 | 0.88 | 0.99 | 0.20 |
| ASNS, ECAD, and TYRP1 | 0.900 | >−0.903 | 0.73 | 0.88 | 0.99 | 0.20 |
| ASNS, TYRP1, and X123 | 0.891 | >−0.751 | 0.73 | 0.88 | 0.99 | 0.20 |
| ASNS, CA4, and CRYAB | 0.847 | >−1.419 | 0.75 | 0.73 | 0.99 | 0.11 |
GOT = glutamic oxaloacetic transaminase 1; TFF3 = trefoil factor 3; FGF13 = fibroblast growth factor 13; SCNN1A = sodium channel, non-voltage gated, 1 alpha subunit; ECAD = E cadherin, type 1.